Skip to main content
. 2023 Aug 10;16(10):1957–1971. doi: 10.1111/cts.13604

FIGURE 1.

FIGURE 1

TXNDC12 is associated with poor prognosis in gliomas. (a) TXNDC12 expression determined by western blotting in glioma and paracancerous tissues. N: normal; T: tumor. (b) Relative protein expression of TXNDC12 in normal human astrocyte and glioma cell lines (U373, A172, U251, U87, LN18, and LN229), obtained by Western blotting. (c) Expression of TXNDC12 in adjacent normal tissues and gliomas of different grades, obtained by immunohistochemistry. (d) Expression of TXNDC12 in adjacent normal tissues and gliomas of different grades obtained using qPCR. (e) Overall survival curves of patients with high or low TXNDC12 expression from TCGA dataset. Data shown represent mean ± SD from three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001. ns, not significant; qPCR, quantitative polymerase chain reaction; TCGA, The Cancer Genome Atlas; WHO, World Health Organization.